June
01,
2023
|
13:59 PM
Europe/Amsterdam
Bayer starts phase II/III study with vericiguat in children with heart failure
Not intended for U.S. and UK Media
Phase II/III study VALOR will assess efficacy, safety and pharmacokinetics of vericiguat in pediatric patients / VALOR is the pivotal study in pediatric heart failure with vericiguat
June
01,
2023
|
08:29 AM
Europe/Amsterdam
Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
Not intended UK Media
Exclusive license agreement includes rights to develop and commercialize Cedilla’s CyclinE1/CDK2 inhibitors / Assets are currently in pre-clinical development with potential to serve patients with high unmet need in underserved indications / …
May
31,
2023
|
08:59 AM
Europe/Amsterdam
Bayer launches unit to develop new precision health consumer products
Digital health solutions to drive transformation of everyday health:
Basel, Switzerland, May 31, 2023 – The Consumer Health Division of Bayer has launched a business unit focused on developing new Precision Health products across its range of everyday health categories. Bayer will prioritize developing products that …
May
25,
2023
|
13:59 PM
Europe/Amsterdam
Bayer presents new data across oncology portfolio at the 2023 ASCO Annual Meeting
Not intended for U.S. and UK Media
Bayer continues to focus on advancing prostate cancer care from early to metastatic stage with darolutamide data in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223 …
May
23,
2023
|
19:07 PM
Europe/Amsterdam
Bayer issues new senior bonds with a volume of 3 billion euros
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Issuance consisted of three tranches with maturities between 3.25 and 10 years and was substantially oversubscribed
May
17,
2023
|
13:59 PM
Europe/Amsterdam
Kerendia™ (finerenone) granted expanded indication in China for broad range of patients with chronic kidney disease and type 2 diabetes
Not intended for U.S. and UK Media
Chinese National Medical Products Administration granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase …
May
16,
2023
|
13:11 PM
Europe/Amsterdam
Funding advances BBI-355, a potentially best-in-class checkpoint kinase 1 (CHK1) inhibitor, through meaningful clinical data readouts in Phase 1/2 POTENTIATE clinical trial
May
16,
2023
|
08:29 AM
Europe/Amsterdam
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
Not intended for UK Media
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries / Asundexian is being evaluated as a potential improved treatment option in …
May
11,
2023
|
07:29 AM
Europe/Amsterdam
Slow start to the year as expected
Bayer Group business performance in the first quarter of 2023:
Group sales stable at 14.389 billion euros (Fx & portfolio adj. minus 1.1 percent)o Accelerated normalization in glyphosate business – good price dynamics in other Crop Science unitso New Pharmaceuticals products deliver strong growth – …
May
11,
2023
|
07:29 AM
Europe/Amsterdam
Four oral presentations and seven poster presentations will share insights into AskBio’s adeno-associated virus research, development and pre-clinical product progress / Breadth of research reinforces AskBio’s continued commitment to the development …
May
10,
2023
|
12:59 PM
Europe/Amsterdam
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
Not intended for UK Media
Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology / Advancing the use of bicycle peptides as a novel targeting approach in …